Financial Performance - The company's revenue for Q1 2024 was ¥90,172,342.02, representing a 25.14% increase compared to ¥72,058,423.64 in Q1 2023[5] - Net profit attributable to shareholders for Q1 2024 was ¥29,687,084.26, an 18.81% increase from ¥24,987,178.21 in the same period last year[5] - The net profit after deducting non-recurring gains and losses decreased by 5.41%, amounting to ¥22,744,459.46 compared to ¥24,044,549.40 in Q1 2023[5] - Basic and diluted earnings per share were both ¥0.45, a decrease of 10.00% from ¥0.50 in the previous year[5] - Total operating revenue for Q1 2024 reached ¥90,172,342.02, an increase of 25.1% compared to ¥72,058,423.64 in the same period last year[23] - The company's net profit for Q1 2024 is not explicitly stated but can be inferred from the increase in retained earnings to ¥356,536,688.71 from ¥326,849,604.45, indicating a growth of 9.0%[22] - Operating profit for Q1 2024 reached CNY 32,127,485.39, up from CNY 28,504,379.46 in the same period last year, reflecting a growth of 9.1%[24] - The company reported a total comprehensive income of CNY 29,687,084.26 for Q1 2024, compared to CNY 24,987,178.21 in the same quarter last year[24] Cash Flow and Investments - The net cash flow from operating activities was ¥566,206.01, down 81.58% from ¥3,073,451.90 in Q1 2023[5] - The company's cash and cash equivalents decreased to ¥238,745,336.87 from ¥253,496,974.51, a decline of 5.8%[20] - The company's cash flow from investment activities was negative at ¥-15,317,843.65, a 47.71% improvement compared to ¥-29,294,592.02 in Q1 2023[12] - Cash flow from operating activities generated a net amount of CNY 566,206.01, a significant decrease from CNY 3,073,451.90 in Q1 2023[26] - The net cash flow from investing activities was -CNY 15,317,843.65, compared to -CNY 29,294,592.02 in Q1 2023, indicating an improvement[27] Assets and Liabilities - The company's total assets at the end of Q1 2024 were ¥1,568,799,996.31, reflecting a 1.57% increase from ¥1,544,589,389.03 at the end of the previous year[5] - Total assets as of March 31, 2024, amounted to ¥1,568,799,996.31, compared to ¥1,544,589,389.03 at the beginning of the year, reflecting a growth of 1.6%[22] - Total liabilities decreased to ¥75,103,153.46 from ¥80,579,630.44, a reduction of 6.1%[22] - The total current assets increased to ¥1,376,735,121.42 from ¥1,362,183,442.36, a rise of 1.1%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,566[14] - The largest shareholder, Tao Chunlei, holds 39.64% of the shares, totaling 26,427,800 shares[14] - The second-largest shareholder, Xu Xinluo, owns 14.59% of the shares, amounting to 9,726,200 shares[14] - The top ten shareholders collectively hold a significant portion of the company's equity, with the first three shareholders alone accounting for over 61%[14] - There are no preferred shareholders with restored voting rights as of the reporting period[14] - The company has a total of 0 shares released from restrictions during this reporting period[17] - The restricted shares held by major shareholders will remain locked until at least March 2027[17] Research and Development - Research and development expenses increased by 118.06% to ¥10,738,916.39, compared to ¥4,924,815.49 in Q1 2023, indicating a significant investment in innovation[12] - Research and development expenses increased to ¥10,738,916.39, a rise of 117.0% compared to ¥4,924,815.49 in the previous year[23] Business Outlook - The company has no plans for new product launches or technological developments mentioned in the current report[16] - There are no indications of market expansion or mergers and acquisitions in the current reporting period[16] - The company has not provided any future performance guidance or outlook in the current report[16] - The company did not report any new mergers or acquisitions during this quarter[28] - The financial report for Q1 2024 was not audited[28]
万邦医药(301520) - 2024 Q1 - 季度财报